Arvinas Email Format

Biotechnology Research
201-500 employees
New Haven, CT, USA

Arvinas is a clinical-stage biotechnology company developing PROTAC targeted protein degraders to treat cancer and neurodegenerative diseases through innovative protein degradation therapies.

Find contacts at Arvinas

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@arvinas.com

Company Overview

Industry
Biotechnology Research
Founded
2013
Headquarters
New Haven, CT, USA
Revenue
$250M-$500M
FUNDING Stage
Public
Key Executives
Randy Teel, Ph.D. (President and Chief Executive Officer), Andrew Saik (Chief Financial Officer and Treasurer), Alex Santini (Chief Commercial Officer)

Tech Stack

Omniture SiteCatalyst

Analytics

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Arvinas?

Arvinas uses the first.last format on arvinas.com, so Jane Smith would be jane.smith@arvinas.com.

Who founded Arvinas and what is the scientific origin of the company?

Arvinas was founded by Yale chemist Craig Crews, Ph.D., whose pioneering research into PROTAC protein degraders formed the scientific basis for the company and its entire drug discovery platform.

What therapeutic areas does Arvinas focus on?

Arvinas is focused on oncology and neurology, with pipeline programs targeting cancers such as breast cancer, prostate cancer, and pancreatic cancer, as well as neurological conditions including Parkinson's disease and spinal-bulbar muscular atrophy.

Has Arvinas received FDA approval for any of its PROTAC drugs?

Yes, Arvinas received FDA approval for VEPPANU (vepdegestrant) in May 2026 for the treatment of ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer, making it the first-ever FDA-approved PROTAC therapy.

How can I find a specific Arvinas contact to reach out to for partnership or business development?

Since Arvinas uses the first.last@arvinas.com format, you can build contact addresses once you have a name. Tools like Clay can help you verify Arvinas employee contact details and enrich your outreach list with accurate, up-to-date information.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles